Compare Stocks: ENGN, KMDA, YDES, and PRTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$1.56 -1.3%	$1.82	$1.40 ▼ $12.25	$105.89M	-0.29	882,492 shs	730,199 shs
KMDA Kamada	$7.77 +0.5%	$8.20	$6.55 ▼ $9.35	$444.51M	0.89	79,541 shs	88,202 shs
PRTA Prothena	$8.20 -0.6%	$8.80	$7.73 ▼ $11.80	$431.91M	-0.29	563,762 shs	385,916 shs
YDES YD Bio	$4.95 +16.7%	$4.94	$1.70 ▼ $18.57	$300.15M	-1.55	236,431 shs	105,142 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	-1.27%	-6.59%	-22.00%	-14.29%	-80.74%
KMDA Kamada	+0.52%	+0.13%	-11.40%	+10.06%	+14.26%
PRTA Prothena	-0.61%	-1.80%	-5.53%	-6.29%	-17.00%
YDES YD Bio	+16.75%	-16.39%	+53.25%	+120.98%	+494,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$1.56 -1.3%	$1.82	$1.40 ▼ $12.25	$105.89M	-0.29	882,492 shs	730,199 shs
KMDA Kamada	$7.77 +0.5%	$8.20	$6.55 ▼ $9.35	$444.51M	0.89	79,541 shs	88,202 shs
PRTA Prothena	$8.20 -0.6%	$8.80	$7.73 ▼ $11.80	$431.91M	-0.29	563,762 shs	385,916 shs
YDES YD Bio	$4.95 +16.7%	$4.94	$1.70 ▼ $18.57	$300.15M	-1.55	236,431 shs	105,142 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	-1.27%	-6.59%	-22.00%	-14.29%	-80.74%
KMDA Kamada	+0.52%	+0.13%	-11.40%	+10.06%	+14.26%
PRTA Prothena	-0.61%	-1.80%	-5.53%	-6.29%	-17.00%
YDES YD Bio	+16.75%	-16.39%	+53.25%	+120.98%	+494,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENGN enGene	2.21	Hold	$11.05	608.04% Upside
KMDA Kamada	3.00	Buy	$13.50	73.75% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	199.65% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ENGN, KMDA, YDES, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	ENGN enGene	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/16/2026	ENGN enGene	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Market Perform ➝ Hold
10/15/2026	ENGN enGene	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/14/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/13/2026	ENGN enGene	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/9/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
9/24/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/22/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy (B-)
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$15.00
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	ENGN enGene	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENGN enGene	N/A	N/A	N/A	N/A	$2.60 per share	N/A
KMDA Kamada	$180.46M	2.48	$0.61 per share	12.66	$4.68 per share	1.66
PRTA Prothena	$9.68M	44.35	N/A	N/A	$5.21 per share	1.57
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENGN enGene	-$117.30M	-$2.07	N/A	N/A	N/A	N/A	-55.79%	-45.17%	12/22/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	20.45	13.40	0.65	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	2.91	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ENGN, KMDA, YDES, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	KMDA Kamada	$0.13	N/A	N/A	N/A	$52.51 million	N/A
11/5/2026	Q3 2026	PRTA Prothena	-$0.21	N/A	N/A	N/A	$9.58 million	N/A
9/8/2026	Q3 2026	ENGN enGene	-$0.4266	-$0.47	-$0.0434	-$0.47	N/A	N/A
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENGN enGene	$1.58	101.35%	N/A	N/A	N/A
KMDA Kamada	$0.13	1.67%	N/A	34.21%	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Latest ENGN, KMDA, YDES, and PRTA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENGN enGene	0.11	10.21	10.21
KMDA Kamada	N/A	4.06	2.29
PRTA Prothena	N/A	25.05	25.05
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENGN enGene	64.16%
KMDA Kamada	20.38%
PRTA Prothena	97.08%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
ENGN enGene	10.50%
KMDA Kamada	36.10%
PRTA Prothena	10.40%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENGN enGene	82	67.02 million	59.98 million	Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
PRTA Prothena	67	52.35 million	46.91 million	Optionable
YDES YD Bio	14	70.79 million	N/A	N/A

ENGN, KMDA, YDES, and PRTA Headlines

Recent News About These Companies

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

October 20, 2026 | globenewswire.com

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

October 6, 2026 | globenewswire.com

Cours YD Bio Limited

September 24, 2026 | zonebourse.comZ

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN, KMDA, YDES, and PRTA Company Descriptions

enGene NASDAQ:ENGN

$1.56 -0.02 (-1.27%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$1.56 +0.00 (+0.32%)

As of 10/23/2026 07:30 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Kamada NASDAQ:KMDA

$7.77 +0.04 (+0.52%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$7.76 -0.01 (-0.13%)

As of 10/23/2026 07:30 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Prothena NASDAQ:PRTA

$8.20 -0.05 (-0.61%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$8.52 +0.33 (+3.96%)

As of 10/23/2026 07:30 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

YD Bio NASDAQ:YDES

$4.95 +0.71 (+16.75%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$5.03 +0.08 (+1.60%)

As of 10/23/2026 07:30 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENGN, KMDA, YDES, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENGN, KMDA, YDES, and PRTA Earnings

Compare Dividends

Latest ENGN, KMDA, YDES, and PRTA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENGN, KMDA, YDES, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN, KMDA, YDES, and PRTA Company Descriptions

enGene NASDAQ:ENGN

Kamada NASDAQ:KMDA

Prothena NASDAQ:PRTA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENGN, KMDA, YDES, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENGN, KMDA, YDES, and PRTA Earnings

Compare Dividends

Latest ENGN, KMDA, YDES, and PRTA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENGN, KMDA, YDES, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN, KMDA, YDES, and PRTA Company Descriptions

enGene NASDAQ:ENGN

Kamada NASDAQ:KMDA

Prothena NASDAQ:PRTA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools